Horizon Therapeutics names new chief business officer

29 August 2019

Ireland-incorporated Horizon Therapeutics (Nasdaq: HZNP) has named Andy Pasternak executive vice president, chief business officer, reporting directly to Timothy Walbert, chairman, president and chief executive officer, effective November 1. He will replace incumbent Robert Carey, who will retire on October 1.

Mr Pasternak will join the company’s executive committee and will lead business development, mergers and acquisitions, corporate strategy, commercial development and portfolio management.

Mr Pasternak will join Horizon from Bain & Company, a global management consulting firm, where he currently leads Bain’s Healthcare practice in the Americas. Prior to joining Bain, he was a founding partner in the Health & Life Sciences practice at Oliver Wyman, a global management consultancy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK